Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 1/20 | 0.56 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.56 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 6/20 | 0.53 |
| ▸ | CCR1 | P32246 | 5/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464520 | 0.94 | DRD2 (0.53) | SLC6A1SLC6A12SLC6A11CCR3DRD2 | |
| SCHEMBL11507337 | 0.88 | HTR7 (0.62) | CCR3DRD2CCR1DRD3ADRA1A | |
| SCHEMBL8174918 | 0.86 | SLC6A1 (0.73) | SLC6A1SLC6A12SLC6A11CCR3DRD2 | |
| SCHEMBL11507328 | 0.85 | HTR7 (0.66) | CCR3DRD2CCR1DRD3ADRA1A | |
| Hydrochloric Acid SCHEMBL8175302 | 0.85 | SLC6A1 (0.71) | SLC6A1SLC6A12SLC6A11CCR3DRD2 | |
| SCHEMBL11508526 | 0.81 | DRD2 (0.52) | CCR3DRD2CCR1DRD3ADRA1A | |
| SCHEMBL11508308 | 0.81 | DRD2 (0.56) | CCR3DRD2CCR1DRD3ADRA1A | |
| SCHEMBL11507790 | 0.80 | DRD2 (0.51) | CCR3DRD2CCR1ADRA1A | |
| SCHEMBL11509380 | 0.78 | DRD2 (0.48) | CCR3DRD2CCR1DRD3ADRA1A | |
| Hydrochloric Acid SCHEMBL11506955 | 0.78 | DRD2 (0.51) | CCR3DRD2CCR1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108020-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-21 | — | — | US | disclosed |
| US-8623884-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20120065216-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | KENNIS LUDO EDMOND JOSEPHINE (BE) | 2012-03-15 | — | — | US | disclosed |
| US-8080557-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-20 | — | — | US | disclosed |
| US-20080039480-A1 | Quinazolinedione Derivatives as Parp Inhibitors | JANSSEN PHARMCEUTICA, NV (BE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039480-A1 | Quinazolinedione Derivatives as Parp Inhibitors | JANSSEN PHARMCEUTICA, NV (BE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108020-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | SLC6A1 4727/4885SLC6A12 4587/4885SLC6A11 4801/4885 |
| US-20080039480-A1 | Quinazolinedione Derivatives as Parp Inhibitors | PARP1, PARP2, PARP3 | SLC6A1 4727/4885SLC6A12 4587/4885SLC6A11 4801/4885 |
| US-20120065216-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | SLC6A1 4727/4885SLC6A12 4587/4885SLC6A11 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.